Across TCGA pan-cancer cohorts, FXYD7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FXYD7 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher FXYD7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FXYD7 expression acts as an unfavorable survival marker.

READ and CHOL are the cancer types where FXYD7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
CHOL	OS	Median	All	0.154	0.793	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: FXYD7 tumor-vs-normal RNA expression · all FXYD7 data types